499 reports of this reaction
1.9% of all ALISKIREN HEMIFUMARATE reports
#10 most reported adverse reaction
MALAISE is the #10 most commonly reported adverse reaction for ALISKIREN HEMIFUMARATE, manufactured by LXO US Inc.. There are 499 FDA adverse event reports linking ALISKIREN HEMIFUMARATE to MALAISE. This represents approximately 1.9% of all 26,137 adverse event reports for this drug.
Patients taking ALISKIREN HEMIFUMARATE who experience malaise should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALAISE is a less commonly reported adverse event for ALISKIREN HEMIFUMARATE, but still significant enough to appear in the safety profile.
In addition to malaise, the following adverse reactions have been reported for ALISKIREN HEMIFUMARATE:
The following drugs have also been linked to malaise in FDA adverse event reports:
MALAISE has been reported as an adverse event in 499 FDA reports for ALISKIREN HEMIFUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALAISE accounts for approximately 1.9% of all adverse event reports for ALISKIREN HEMIFUMARATE, making it a notable side effect.
If you experience malaise while taking ALISKIREN HEMIFUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.